Literature DB >> 27521365

Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Matthew L Boisen1, Robert W Cross2, Jessica N Hartnett3, Augustine Goba4, Mambu Momoh5, Mohamed Fullah4, Michael Gbakie4, Sidiki Safa4, Mbalu Fonnie4, Francis Baimba4, Veronica J Koroma4, Joan B Geisbert2, Stephanie McCormick6, Diana K S Nelson7, Molly M Millett7, Darin Oottamasathien7, Abby B Jones7, Ha Pham7, Bethany L Brown7, Jeffrey G Shaffer8, John S Schieffelin9, Brima Kargbo10, Momoh Gbetuwa11, Sahr M Gevao5, Russell B Wilson6, Kelly R Pitts7, Thomas W Geisbert2, Luis M Branco12, Sheik H Khan4, Donald S Grant4, Robert F Garry13.   

Abstract

BACKGROUND: The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) could exceed 5 days. Here we describe the development and field validation of the ReEBOV Antigen Rapid Test (ReEBOV RDT) to aid triage of individuals with suspected EVD.
METHODS: Samples from patients with suspected EVD were submitted to Kenema Government Hospital, Sierra Leone, for Lassa fever and EVD screening throughout 2014. Banked residual clinical samples were tested in November 2014 and January 2015 in a blinded field trial to estimate the clinical effectiveness of the ReEBOV RDT, compared with EBOV-specific qRT-PCR.
RESULTS: Preliminary ReEBOV RDT performance demonstrated a positive percentage agreement (PPA) of 91.1% (195 of 214 results; 95% confidence interval [CI], 86.5%-94.6%) and a negative percentage agreement (NPA) of 90.2% (175 of 194; 95% CI, 85.1%-94.0%). The final estimates used by the Food and Drug Administration to determine whether to grant emergency use authorization for the test, which excluded a qRT-PCR reference method threshold cutoff, were a PPA of 62.1% (72 of 116 results; 95% CI, 52.6%-70.9%) and a NPA of 96.7% (58 of 60; 95% CI, 88.5%-99.6%), with a diagnostic likelihood of 18.6. A subsequent, independent evaluation by the World Health Organization generated results consistent with the preliminary performance estimates.
CONCLUSIONS: The ReEBOV RDT demonstrated the potential to provide clinically effective rapid and accurate point-of-care test results and, thus, to be a powerful tool for increasing triage efficiency.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Ebola; clinical; lateral flow immunoassay; point of care; validation

Mesh:

Substances:

Year:  2016        PMID: 27521365      PMCID: PMC5050478          DOI: 10.1093/infdis/jiw261

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses.

Authors:  Adrienne R Trombley; Leslie Wachter; Jeffrey Garrison; Valerie A Buckley-Beason; Jordan Jahrling; Lisa E Hensley; Randal J Schoepp; David A Norwood; Augustine Goba; Joseph N Fair; David A Kulesh
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

2.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

3.  Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014.

Authors:  Florian Vogt; Gabriel Fitzpatrick; Gabriela Patten; Rafael van den Bergh; Kathryn Stinson; Luigi Pandolfi; James Squire; Tom Decroo; Hilde Declerck; Michel Van Herp
Journal:  Euro Surveill       Date:  2015

4.  ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.

Authors:  Mara Jana Broadhurst; John Daniel Kelly; Ann Miller; Amanda Semper; Daniel Bailey; Elisabetta Groppelli; Andrew Simpson; Tim Brooks; Susan Hula; Wilfred Nyoni; Alhaji B Sankoh; Santigi Kanu; Alhaji Jalloh; Quy Ton; Nicholas Sarchet; Peter George; Mark D Perkins; Betsy Wonderly; Megan Murray; Nira R Pollock
Journal:  Lancet       Date:  2015-06-25       Impact factor: 79.321

5.  Clinical illness and outcomes in patients with Ebola in Sierra Leone.

Authors:  John S Schieffelin; Jeffrey G Shaffer; Augustine Goba; Michael Gbakie; Stephen K Gire; Andres Colubri; Rachel S G Sealfon; Lansana Kanneh; Alex Moigboi; Mambu Momoh; Mohammed Fullah; Lina M Moses; Bethany L Brown; Kristian G Andersen; Sarah Winnicki; Stephen F Schaffner; Daniel J Park; Nathan L Yozwiak; Pan-Pan Jiang; David Kargbo; Simbirie Jalloh; Mbalu Fonnie; Vandi Sinnah; Issa French; Alice Kovoma; Fatima K Kamara; Veronica Tucker; Edwin Konuwa; Josephine Sellu; Ibrahim Mustapha; Momoh Foday; Mohamed Yillah; Franklyn Kanneh; Sidiki Saffa; James L B Massally; Matt L Boisen; Luis M Branco; Mohamed A Vandi; Donald S Grant; Christian Happi; Sahr M Gevao; Thomas E Fletcher; Robert A Fowler; Daniel G Bausch; Pardis C Sabeti; S Humarr Khan; Robert F Garry
Journal:  N Engl J Med       Date:  2014-10-29       Impact factor: 91.245

6.  Evolution of ebola virus disease from exotic infection to global health priority, Liberia, mid-2014.

Authors:  M Allison Arwady; Luke Bawo; Jennifer C Hunter; Moses Massaquoi; Almea Matanock; Bernice Dahn; Patrick Ayscue; Tolbert Nyenswah; Joseph D Forrester; Lisa E Hensley; Benjamin Monroe; Randal J Schoepp; Tai-Ho Chen; Kurt E Schaecher; Thomas George; Edward Rouse; Ilana J Schafer; Satish K Pillai; Kevin M De Cock
Journal:  Emerg Infect Dis       Date:  2015-04       Impact factor: 6.883

Review 7.  Mapping the zoonotic niche of Lassa fever in Africa.

Authors:  Adrian Q N Mylne; David M Pigott; Joshua Longbottom; Freya Shearer; Kirsten A Duda; Jane P Messina; Daniel J Weiss; Catherine L Moyes; Nick Golding; Simon I Hay
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-06-17       Impact factor: 2.184

8.  Lassa fever in post-conflict sierra leone.

Authors:  Jeffrey G Shaffer; Donald S Grant; John S Schieffelin; Matt L Boisen; Augustine Goba; Jessica N Hartnett; Danielle C Levy; Rachael E Yenni; Lina M Moses; Mohammed Fullah; Mambo Momoh; Mbalu Fonnie; Richard Fonnie; Lansana Kanneh; Veronica J Koroma; Kandeh Kargbo; Darin Ottomassathien; Ivana J Muncy; Abigail B Jones; Megan M Illick; Peter C Kulakosky; Allyson M Haislip; Christopher M Bishop; Deborah H Elliot; Bethany L Brown; Hu Zhu; Kathryn M Hastie; Kristian G Andersen; Stephen K Gire; Shervin Tabrizi; Ridhi Tariyal; Mathew Stremlau; Alex Matschiner; Darryl B Sampey; Jennifer S Spence; Robert W Cross; Joan B Geisbert; Onikepe A Folarin; Christian T Happi; Kelly R Pitts; F Jon Geske; Thomas W Geisbert; Erica Ollmann Saphire; James E Robinson; Russell B Wilson; Pardis C Sabeti; Lee A Henderson; S Humarr Khan; Daniel G Bausch; Luis M Branco; Robert F Garry
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

9.  Prognostic Indicators for Ebola Patient Survival.

Authors:  Samuel J Crowe; Matthew J Maenner; Solomon Kuah; Bobbie Rae Erickson; Megan Coffee; Barbara Knust; John Klena; Joyce Foday; Darren Hertz; Veerle Hermans; Jay Achar; Grazia M Caleo; Michel Van Herp; César G Albariño; Brian Amman; Alison Jane Basile; Scott Bearden; Jessica A Belser; Eric Bergeron; Dianna Blau; Aaron C Brault; Shelley Campbell; Mike Flint; Aridth Gibbons; Christin Goodman; Laura McMullan; Christopher Paddock; Brandy Russell; Johanna S Salzer; Angela Sanchez; Tara Sealy; David Wang; Gbessay Saffa; Alhajie Turay; Stuart T Nichol; Jonathan S Towner
Journal:  Emerg Infect Dis       Date:  2016-02       Impact factor: 6.883

10.  The face of Ebola: changing frequency of haemorrhage in the West African compared with Eastern-Central African outbreaks.

Authors:  Stefano Petti; Giuseppe Alessio Messano; Enzo Maria Vingolo; Luigi Tonino Marsella; Crispian Scully
Journal:  BMC Infect Dis       Date:  2015-12-11       Impact factor: 3.090

View more
  15 in total

1.  Diagnostic Laboratories' Capacities and Preparedness for Emerging Viral Diseases in Guinea and Mali.

Authors:  Tiffany Zhang Teng; Abdoul Habib Beavogui; Bassirou Diarra; Alexandre Delamou; Jane Holl; Almoustapha Issiaka Maiga; Yeya Dit Sadio Sarro; Amadou Kone; Bourahima Kone; Djeneba Bocar Fofana; Etienne Dembele; Mamadou Saliou Sow; Moussa Seydi; Aboubacar Alassane Oumar; Mahamadou Diakité; Souleymane Diallo; Seydou Doumbia; Sounkalo Dao; Robert L Murphy; Mamoudou Maiga
Journal:  Infect Dis Diagn Treat       Date:  2020-02-21

Review 2.  Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis.

Authors:  Basilua Andre Muzembo; Kei Kitahara; Ayumu Ohno; Ngangu Patrick Ntontolo; Nlandu Roger Ngatu; Keinosuke Okamoto; Shin-Ichi Miyoshi
Journal:  Bull World Health Organ       Date:  2022-06-01       Impact factor: 13.831

3.  Analysis of CD8+ T cell response during the 2013-2016 Ebola epidemic in West Africa.

Authors:  Saori Sakabe; Brian M Sullivan; Jessica N Hartnett; Refugio Robles-Sikisaka; Karthik Gangavarapu; Beatrice Cubitt; Brian C Ware; Dylan Kotliar; Luis M Branco; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Donald S Grant; Robert F Garry; Kristian G Andersen; Juan Carlos de la Torre; Pardis C Sabeti; John S Schieffelin; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

Review 4.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

5.  Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.

Authors:  Cassio M Fontes; Barbara D Lipes; Jason Liu; Krystle N Agans; Aiwei Yan; Patricia Shi; Daniela F Cruz; Garrett Kelly; Kelli M Luginbuhl; Daniel Y Joh; Stephanie L Foster; Jacob Heggestad; Angus Hucknall; Maiken H Mikkelsen; Carl F Pieper; Roarke W Horstmeyer; Thomas W Geisbert; Michael D Gunn; Ashutosh Chilkoti
Journal:  Sci Transl Med       Date:  2021-04-07       Impact factor: 17.956

6.  Responding to ever-changing epidemiological dynamics of Ebola virus disease.

Authors:  Yuki Maehira; Yohei Kurosaki; Tomoya Saito; Jiro Yasuda; Masayoshi Tarui; Denis J M Malvy; Tsutomu Takeuchi
Journal:  BMJ Glob Health       Date:  2016-11-24

7.  Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.

Authors:  Matthew L Boisen; Jessica N Hartnett; Jeffrey G Shaffer; Augustine Goba; Mambu Momoh; John Demby Sandi; Mohamed Fullah; Diana K S Nelson; Duane J Bush; Megan M Rowland; Megan L Heinrich; Anatoliy P Koval; Robert W Cross; Kayla G Barnes; Anna E Lachenauer; Aaron E Lin; Mahan Nekoui; Dylan Kotliar; Sarah M Winnicki; Katherine J Siddle; Michael Gbakie; Mbalu Fonnie; Veronica J Koroma; Lansana Kanneh; Peter C Kulakosky; Kathryn M Hastie; Russell B Wilson; Kristian G Andersen; Onikepe O Folarin; Christian T Happi; Pardis C Sabeti; Thomas W Geisbert; Erica Ollmann Saphire; S Humarr Khan; Donald S Grant; John S Schieffelin; Luis M Branco; Robert F Garry
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

8.  Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.

Authors:  Trevor V Gale; Timothy M Horton; Donald S Grant; Robert F Garry
Journal:  PLoS Negl Trop Dis       Date:  2017-09-18

9.  Development of Mobile Laboratory for Viral Hemorrhagic Fever Detection in Africa.

Authors:  Manfred Weidmann; Ousmane Faye; Oumar Faye; Ahmed Abd El Wahed; Pranav Patel; Christophe Batejat; Jean Claude Manugerra; Aimee Adjami; Matthias Niedrig; Frank T Hufert; Amadou A Sall
Journal:  J Infect Dis       Date:  2018-10-05       Impact factor: 5.226

10.  Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet.

Authors:  Chantal B Reusken; Ramona Mögling; Pieter W Smit; Roland Grunow; Giuseppe Ippolito; Antonino Di Caro; Marion Koopmans
Journal:  Euro Surveill       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.